Alopecia Areata Patient-Reported Outcomes: Defining Treatment Success and Monitoring Response

Dr. Ungar says the evidence clearly shows a positive effect of JAK inhibitors on patient-reported outcomes and quality of life. In THRIVE-AA1 and THRIVE-AA2, more than 40 percent and potentially close to 50 percent of patients on the approved 8 mg deuruxolitinib dose reported being satisfied or very satisfied, compared with under 5 percent and under 2 percent on placebo. In the ritlecitinib trial, two-thirds of patients were satisfied with their hair growth at week 24, versus 14.5 percent on placebo. For baricitinib, a retrospective study found Skindex-16 scores improving from 57.1 at baseline to 30 at week 48.

For the Case 2 patient, he stresses that scalp loss and psychosocial burden are closely tied, yet the burden is not always visible. Treatment success is also broader than full regrowth. Partial regrowth, a feeling of control, and less fear of progression can leave patients substantially better, so success means the patient is happy with her hair. All three approved options would suit her, with access and approval as practical factors.

On monitoring, Dr. Ungar usually adds low-dose oral minoxidil from the start, an off-label approach supported by some data and experience. The timeline for judging response depends on baseline severity. Patients nearer the moderate end should show meaningful regrowth within six months, and no regrowth by then may signal a need to switch. With complete scalp loss, he allows a year and targets about 30 percent regrowth. Although switching data are still developing, studies and his own patients show that people who fail one JAK inhibitor may respond to another.

Our next episode, "Case 3: Alopecia Areata with Facial Involvement," presents a man whose rapid flare now involves his eyebrows and beard.